Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.
about
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BAspects of prophylactic treatment of hemophiliaMRI scores of ankle joints in children with haemophilia--comparison with clinical data.Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIIIProphylaxis in developed and in emerging countries.Gene therapy ethics and haemophilia: an inevitable therapeutic future?Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.A global view on prophylaxis: possibilities and consequences.When to start and when to stop primary prophylaxis in patients with severe haemophilia.North American prophylaxis studies for persons with severe haemophilia: background, rationale and design.Factor replacement therapy in haemophilia--are there models for developing countries?Home management of haemophilia.Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?Treatment of hemophilia: a review of current advances and ongoing issuesRecombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.Persons with Haemophilia in Sweden- Experiences and Strategies in Everyday Life. A Single Centre StudyTowards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary.Optimizing factor prophylaxis for the haemophilia population: where do we stand?Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs.Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.Osteoporosis in haemophilic patient, rehabilitative aspects.Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.Optimal haemophilia care versus the reality.Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy.New treatments in hemophilia: insights for the clinician.Barriers and perceived limitations to early treatment of hemophilia.Prophylaxis in adults with haemophilia.Identifying and overcoming barriers to prophylaxis in the management of haemophilia.Optimizing outcomes for patients with severe haemophilia A.Intracranial haemorrhage in haemophilia A and B.Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sPrimary prophylaxis in children with haemophilia.Secondary prophylaxis in adolescent and adult haemophiliacs.Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.Current options and new developments in the treatment of haemophilia.Joint protection in haemophilia.The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe.Hemophilia and prophylaxis.Changing paradigm of prophylaxis with longer acting factor concentrates.
P2860
Q24234413-E7CE9A61-B870-4A82-936E-C51EDC281D38Q28078562-21BC1203-15B7-4B69-BCC8-60FD65175B3AQ30986499-72A39F6B-90CB-4906-BE26-2376166AB681Q33715399-3BBD72A4-6BE8-4125-A142-704B3EB2DDD4Q34550081-C66ABA03-F89C-4A48-8E3F-A5B295181BEDQ34636878-67E0D760-AF67-4120-8C61-B617CE88B119Q35076713-B4DB2F17-38B2-430D-BB48-1662296801B9Q35106858-97EE3071-6A85-4C87-98B8-0E78FC2E349FQ35112430-03F8CC48-F7BB-4EF7-8515-9DAEE3EB66E6Q35112433-9D69C733-3926-4CC3-AE7D-AF7E10CD14DAQ35112437-4364CB71-FBDF-4F7B-8691-068772DB1959Q35163619-9E3DB583-2F3B-41F4-9002-929FC53D0242Q35666730-F58F875E-B75E-4613-9F0C-230816631996Q35666740-780A66D5-D9CE-496F-9EB8-E7413FC9ED6EQ35683781-FABA8346-90B3-45FD-921A-126789225AABQ35692016-7B16B565-2956-4E19-A566-06046D1999B4Q35797283-5DFF60BA-F50A-45DE-B83C-26CFE33C440DQ35915682-627883EC-0C7E-4B51-BC63-D9507A60FCD2Q35915686-8284865F-8249-4342-B84E-F29250F86596Q35969194-80293074-8EE8-40F3-9C9F-42EDACC3E3CFQ36250920-41405B91-0DF5-4FFB-B373-AC1DE0A2F5A6Q36333470-CC463DE0-521B-4CB0-9A55-9822DE9897DEQ36380181-F92B8148-0F2D-405A-82F2-E0AE2ABCF710Q36399847-9DB4D670-1929-4337-8AB6-68C795DE8BD5Q36473108-E624A752-C6B6-494D-828F-F1349A8E9277Q36612681-84328593-25F7-4466-842B-02A7E5E9D05CQ36863077-E3331285-249B-44A7-A948-C3B1072D27C1Q36904925-7500D308-1EAD-4A86-BC3B-BEDC2F3FC6E9Q36904929-D25468A7-E040-4B7C-941A-EDFA1442A924Q36932769-B3FD3416-560F-4B92-B86A-8E420FACA274Q37032896-959EC070-A8B4-4132-85EA-A3F3D8ADD356Q37098836-75B4ADCC-27B4-4D71-9798-404DFF81FB98Q37119644-5B1D9DD5-6B43-4B1D-85D6-FA6723DA4080Q37119647-89EE7E12-DD6A-4727-8CF4-38D35C3582ABQ37719683-6DB4607E-24D1-4397-BD17-018EDF0E751BQ37841547-12CADF04-46CD-4194-9086-FBADF7133CD4Q37912258-762414E2-534E-47E3-A451-B097CB581251Q38038876-8467AD62-B5C4-4316-9B1F-4475BCA7867AQ38056467-88A660E4-0EB2-4C1B-932C-2085C9886EDBQ38206858-9E898624-0F35-4EF8-91E6-AC727A9AB58B
P2860
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Primary prophylaxis in severe ...... age but can be individualized.
@en
Primary prophylaxis in severe ...... age but can be individualized.
@nl
type
label
Primary prophylaxis in severe ...... age but can be individualized.
@en
Primary prophylaxis in severe ...... age but can be individualized.
@nl
prefLabel
Primary prophylaxis in severe ...... age but can be individualized.
@en
Primary prophylaxis in severe ...... age but can be individualized.
@nl
P2093
P2860
P1476
Primary prophylaxis in severe ...... age but can be individualized.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.1999.01463.X
P407
P50
P577
1999-06-01T00:00:00Z